Nikhil Khushalani, MD, Soft Tissue and Melanoma Section Chief and Director of the IL-2 Program, and Joseph Prah, MD, former Assistant Professor in the Department of Medicine, discuss recent advances in cancer chemotherapeutics, including targeted therapies, FDA approval for vemurafenib and current/upcoming clinical trials. Joining the conversation is melanoma survivor Drew Thompson.
